218 related articles for article (PubMed ID: 32623076)
1. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature.
Tang Z; Fang R; Tong G; Liu P; Ou Z; Tang Y
Lung Cancer; 2020 Aug; 146():335-340. PubMed ID: 32623076
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.
Liu Y; Long L; Liu J; Zhu L; Luo F
Front Oncol; 2021; 11():749682. PubMed ID: 34692530
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma.
Hong HZ; Li JK; Zhang JT; Li HJ; Peng LS; Wu YL; Zhong WZ
Lung Cancer; 2023 Jul; 181():107220. PubMed ID: 37263181
[TBL] [Abstract][Full Text] [Related]
4. Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab.
Kumar V; Dave V; Harris J; Huang Y
Immunotherapy; 2017 Sep; 9(12):955-961. PubMed ID: 28971752
[TBL] [Abstract][Full Text] [Related]
5. Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report.
Qiu ZX; Zhou P; Wang K
Onco Targets Ther; 2019; 12():8595-8600. PubMed ID: 31802895
[TBL] [Abstract][Full Text] [Related]
6. Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.
Pang LL; Liao J; Huang YH; Gan JD; Zhuang WT; Lv Y; Liang WT; Zhang L; Fang WF
Int J Cancer; 2023 Jun; 152(11):2338-2350. PubMed ID: 36631999
[TBL] [Abstract][Full Text] [Related]
7. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
Kim C; Rajan A; DeBrito PA; Giaccone G
Transl Lung Cancer Res; 2016 Dec; 5(6):720-726. PubMed ID: 28149767
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.
Zhou N; Tang H; Yu S; Lin Y; Wang Y; Wang Y
Front Immunol; 2022; 13():1001414. PubMed ID: 36561745
[TBL] [Abstract][Full Text] [Related]
9. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
10. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
11. Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma.
Chen B; Chen X; Zhou P; Yang L; Ren J; Yang X; Li W
Respir Res; 2019 Nov; 20(1):262. PubMed ID: 31752892
[TBL] [Abstract][Full Text] [Related]
12. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
13. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Wang L; Zhao D; Qin K; Rehman FU; Zhang X
Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
[TBL] [Abstract][Full Text] [Related]
14. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
15. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease.
Zhou N; Lin Y; Peng X; Wang Y; Wang Y
Lung Cancer; 2019 Dec; 138():116-123. PubMed ID: 31683094
[TBL] [Abstract][Full Text] [Related]
16. Polymyositis as a paraneoplastic syndrome of a patient with primary pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.
Lei Y; Liu C; Wan X; Yang Y; Yao Y; Luo L; Huang T; Li J
J Cardiothorac Surg; 2022 May; 17(1):120. PubMed ID: 35581657
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
18. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
19. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
20. Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1: A case report.
Sasaki A; Kato T; Ujiie H; Cho Y; Sato M; Kaji M
Int J Surg Case Rep; 2021 Feb; 79():431-435. PubMed ID: 33529823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
